

Other version: http://annonc.oxfordjournals.org/content/15/5/759.long
![]() |
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial |
|
Authors | ![]() | |
Published in | Annals of oncology. 2004, vol. 15, no. 5, p. 759-64 | |
Abstract | A phase I-II multicenter trial was conducted to define the maximum tolerated dose (MTD) according to tolerance and toxicity (primary objective), as well as to describe the clinical activity, in terms of response and survival (secondary objectives), of a combination of 5-fluorouracil (5-FU) in protracted continuous intravenous infusion (p.i.v.) with docetaxel and cisplatin for patients with advanced gastric cancer. | |
Keywords | Adult — Aged — Antineoplastic Combined Chemotherapy Protocols/therapeutic use — Carcinoma/drug therapy/pathology — Cisplatin/administration & dosage — Female — Fluorouracil/administration & dosage — Humans — Infusions, Intravenous — Male — Maximum Tolerated Dose — Middle Aged — Stomach Neoplasms/drug therapy/pathology — Survival Analysis — Taxoids/administration & dosage | |
Identifiers | PMID: 15111343 | |
Full text |
![]() ![]() Other version: http://annonc.oxfordjournals.org/content/15/5/759.long |
|
Structures | ||
Research group | Groupe Roth Arnaud (oncologie) (285) | |
Citation (ISO format) | ROTH, Arnaud et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. In: Annals of oncology, 2004, vol. 15, n° 5, p. 759-64. doi: 10.1093/annonc/mdh187 https://archive-ouverte.unige.ch/unige:42140 |